30 results on '"Lilly, Michael"'
Search Results
2. Association of elevated serum CEA with visceral metastasis and distinctive circulating tumor DNA alterations in castrate-resistant prostate cancer.
3. Serial ctDNA profiling in patients with metastatic prostate cancer undergoing treatment with radium-223.
4. Differences in the tumor genomic landscape between African Americans (AA) and Caucasians (CA) advanced prostate cancer (aPC) patients (pts) by comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA).
5. A phase II study to evaluate the effects of docetaxel plus lycopene in advanced castrate-resistant prostate cancer.
6. Preliminary results from a phase II trial of docetaxel before castration with degarelix in men with newly diagnosed metastatic prostate cancer.
7. Differences in the genomic landscape of advanced prostate cancer (aPC) patients (pts) with BRCA1 versus BRCA2 mutations as detected by machine learning analysis of the comprehensive genomic profile (CGP) of cell-free DNA (cfDNA).
8. Real-world prevalence of homologous recombination repair gene (BRCA1/2 and ATM) mutations (HRRm) in patients (pts) with advanced prostate cancer (aPC) as detected by comprehensive genomic profiling (CGP) of circulating cell-free DNA (cfDNA).
9. Phase II trial of opaganib in patients with metastatic castration-resistant prostate cancer progressing on abiraterone or enzalutamide (NCT04207255).
10. Identification of actionable BRAF mutations and their genomic associations in advanced prostate cancer.
11. Prognostic implications of gene amplifications identified by circulating tumor DNA (ctDNA) analysis in metastatic prostate cancer (mPC).
12. Circulating tumor (ct) DNA-based comprehensive genomic profiling to identify microsatellite instability (MSI) and defective DNA damage repair (DDR) in prostate cancer (PCa) patients.
13. Immune-stimulatory gene expression in stroma cells of African-American prostate cancer tissues.
14. Profiling of genomic alterations in MAPK/ERK signaling in a large cohort of metastatic prostate cancer (mPC) patients.
15. Circulating tumor (ct) DNA-based genomic profile of prostate cancer (PCa) patients with elevated carcinoembryonic antigen (CEA).
16. Discovery of targetable mutational signatures in advanced prostate cancer (aPC) using machine learning and next-generation sequencing (NGS) of circulating tumor DNA (ctDNA).
17. Genomic changes of AR in ctDNA prior to enzalutamide in men with mCRPC after abiraterone acetate.
18. Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing
19. Landscape of BRCA1 and BRCA2 germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreatic, or prostate cancer.
20. Association of genomic alterations (GAs) in circulating tumor DNA (ctDNA) with progression on abiraterone acetate (AA) or enzalutamide (enza) in advanced prostate cancer.
21. Detection of actionable BRAF missense mutations by ctDNA-based genomic analysis in prostate cancer.
22. Comprehensive analysis of AR alterations in cell free DNA from prostate cancer patients.
23. Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing.
24. Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy.
25. Profiling of circulating tumor (ct)-DNA for potentially actionable targets in prostate cancer (PCa).
26. Genomic profiling of metastatic prostate cancer through analysis of circulating tumor DNA (ctDNA).
27. A phase I trial of docetaxel combined with synthetic lycopene in subjects with metastatic prostate cancer.
28. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer
29. SWOG S0925: A randomized phase 2 study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer.
30. Generation of virtual control groups for single-arm prostate cancer (PCa) adjuvant trials.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.